EX-99.3 4 c19351exv99w3.htm UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS exv99w3
 

Exhibit 99.3
BROOKWOOD PHARMACEUTICALS, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET
AS OF JUNE 30, 2007
         
    June 30  
    2007  
 
       
ASSETS
       
 
       
Current Assets:
       
Cash and cash equivalents
  $ 4,420,943  
Accounts receivable, net
    3,458,438  
Inventory
    446,273  
Prepayments and other current assets
    213,804  
 
     
Total Current Assets
    8,539,458  
 
       
Property and Equipment, net
    5,426,541  
 
       
Other Assets
       
Intangible assets, net
    1,270,794  
Other long-term assets
    2,000  
 
     
Total Other Assets
    1,272,794  
 
       
 
     
TOTAL ASSETS
  $ 15,238,793  
 
     
 
       
LIABILITIES AND STOCKHOLDERS’ EQUITY
       
 
       
Current Liabilities
       
Accounts payable
  $ 692,063  
Accounts payable — parent company
    30,277  
Accrued liabilities
    279,760  
Unearned revenue
    2,770,064  
Current portion of long-term debt
    252,199  
Deferred income taxes
    45,000  
 
     
Total Current Liabilities
    4,069,363  
 
       
Long-Term Debt
    241,093  
 
       
Deferred income taxes
    6,000  
 
       
Stockholder equity
       
Preferred Stock
    10,000  
Common Stock
    10  
Additional paid-in capital
    8,989,879  
Retained earnings
    1,922,448  
 
     
Total Stockholders’ equity
    10,922,337  
 
       
 
     
TOTAL LIABILITIES AND STOCKHOLDER EQUITY
  $ 15,238,793  
 
     

 


 

BROOKWOOD PHARMACEUTICALS, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006
                 
    2007     2006  
Revenues
               
Contract revenues
  $ 6,857,749     $ 4,855,599  
Intellectual property revenues, net of direct expenses
    35,730       57,222  
Polymer revenue
    1,594,798       1,045,013  
 
           
 
    8,488,277       5,957,834  
 
               
Cost of Sales
               
Direct expenses
    2,924,395       2,311,565  
Overhead
    1,814,672       1,202,760  
 
           
 
    4,739,067       3,514,325  
 
               
 
           
Gross Margin
    3,749,210       2,443,509  
 
           
 
               
Other Operating Expenses
               
Research and development
    330,348       173,867  
Selling, general and administrative
    1,846,601       1,438,946  
 
           
 
    2,176,949       1,612,813  
 
               
 
           
Income from Operations
    1,572,261       830,696  
 
           
 
               
Other Income (Expense)
    50,938       (9,664 )
 
               
Net Income before Income Taxes
    1,623,199       821,032  
 
           
 
               
Net Income Tax Expense
    572,525       188,932  
 
           
Net Income
  $ 1,050,674     $ 632,100  
 
           

 


 

BROOKWOOD PHARMACEUTICALS, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2007 AND 2006
                 
    2007     2006  
 
               
Cash Flows from Operating Activities
               
Net Income
  $ 1,050,674     $ 632,100  
 
               
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    397,173       346,722  
Stock-based compensation
    111,235       31,110  
Change in operating assets and liabilities:
               
Accounts receivable, net
    859,795       (872,643 )
Inventory
    (10,019 )     99,117  
Prepayments and other current assets
    (23,054 )     (59,273 )
Accounts payable
    (88,192 )     (525,997 )
Accrued liabilities
    145,506       41,809  
Unearned revenue
    (540,577 )     283,741  
 
           
Net Cash Provided by (used in) Operating Activities
    1,902,541       (23,314 )
 
           
 
               
Cash Flows from Investing Activities
               
Payment for intangible assets, net of reimbursement
    74,620       (72,618 )
Capital expenditures
    (354,818 )     (178,587 )
 
           
Net Cash Used by Investing Activities
    (280,198 )     (251,205 )
 
           
 
               
Cash Flows from Financing Activities
               
Proceeds from issuance of preferred stock
          2,000,000  
 
           
Net Cash Provided by Financing Activities
          2,000,000  
 
           
 
               
Increase in Cash and Cash equivalents
    1,622,343       1,725,481  
 
           
Cash and Cash Equivalents at Beginning of Period
    2,798,600       543,733  
 
           
Cash and Cash Equivalents at End of Period
  $ 4,420,943     $ 2,269,214